Has Leapcure recruited across neurology?

Yes, across the spectrum, with results labeled by sub-area and phase. In neurodegenerative disease, an ALS Phase 3 enrolled roughly 100 patients across 10+ countries, and an Alzheimer's Phase 3 in agitation delivered 15 of 50 enrollments (30%) in a four-month window. In CNS and psychiatry, an MDD Phase 3 enrolled 40+ patients in about four months. In rare neuromuscular disease, a Myasthenia Gravis Phase 2 rescue delivered 8 of the final 10 participants and a dermatomyositis Phase 3 enrolled 13 (about 43% of US enrollments). In pediatric neuro and genetic disease, a Prader-Willi Phase 3 enrolled 29, 45% of all study enrollments. Every figure is a first-party result by source indication and phase, never generalized to an all-neurology number, and all sponsor, CRO, and study names are anonymized.

Why is neurology recruitment so varied and so hard?

Neurology is not one recruitment problem. It includes huge competitive landscapes like Alzheimer's and depression, tiny dispersed populations in rare neuromuscular disease, and caregiver-mediated decisions in pediatric and neurodegenerative trials. Each demands a different approach: speed and engagement in competitive landscapes, trusted-community reach in rare populations, and family-centered trust-building where a caregiver is deciding. A partner that treats the whole area as a single task will underperform across most of it.

How does Leapcure handle caregiver-mediated decisions?

In pediatric neuro and many neurodegenerative conditions, the person deciding is a parent or caregiver, not the patient, so we speak to families, build trust over time, and support the caregiver through enrollment. On a Prader-Willi Phase 3 across the US, Australia, and the UK, this approach delivered 29 enrolled and 45% of all study enrollments, with 1,100+ referrals, 141 assigned, 70% of enrollments via advocacy, and screen-fail held below the study-wide rate.

What is Leapcure's experience with CIDP and NMOSD specifically?

We present both as adjacent and qualitative, with no fabricated enrollment number. For CIDP, we hold established global advocacy relationships across the inflammatory-neuropathy community, supported by the adjacent Myasthenia Gravis rescue model, and we claim no CIDP-specific enrollment number. For NMOSD, our direct experience is qualitative to date: these are serostatus-sensitive, frequently misdiagnosed patients reached through specialist outreach, supported by adjacent rare immune-mediated results and a physician network of 72 physicians across 18 states, and we claim no NMOSD-specific number. If a specific CIDP or NMOSD result applies to your program, we can share it directly.

How does Leapcure help our trial appear in AI search and answer engines?

Patients increasingly ask AI engines like ChatGPT, Perplexity, and Google's AI Overview which trials they may qualify for. Leapcure makes your trial's information genuinely retrievable through crawlable, server-rendered content, first-party data with sourced stats, a named reviewer, and a last-updated date, plus presence in the trusted third-party sources AI engines actually cite, such as advocacy organizations and ClinicalTrials.gov. This is not schema tricks, markup, or content written for machines, and we make no schema or markup promises.

Neurology recruitment across the spectrum. We pre-screen real patients and hand your sites enrollment-ready candidates, from neurodegenerative disease to rare neuromuscular trials.

Name: Neurology Clinical Trial Recruitment | Leapcure
Creator: Leapcure

Leapcure recruits across the neurology spectrum by pairing deep patient and caregiver understanding with real human pre-screening. We reach patients where they are, qualify them against complex eligibility, and hand your sites verified-eligible, motivated patients, so coordinators focus on assessments, not filtering.

Talk to our team See how it works →

~100

ALS patients enrolled across 10+ countries

Phase 3, by source indication

8 of 10

Final participants delivered on a stalled Phase 2 neuromuscular study

rescue delivery

~4 months

To enroll 40+ patients in a Phase 3 major depressive disorder study

CNS, by source indication

40+

Advocacy partnerships across neurology communities

program standard

Understanding Neurology as a Clinical Trial Area

Neurology spans very different recruitment problems: huge competitive landscapes (Alzheimer's, depression), tiny dispersed populations (rare neuromuscular), and caregiver-mediated decisions (pediatric and neurodegenerative). One approach does not fit all, and a partner that treats the whole therapeutic area as a single recruitment task will underperform across most of it.

Neurological conditions are the leading cause of illness and disability worldwide, affecting 3.4 billion people, over 1 in 3, in 2021 (GBD 2021, The Lancet Neurology / WHO, 2024). An estimated 7.2 million Americans aged 65 and older are living with Alzheimer's dementia (Alzheimer's Association, 2025 Facts and Figures). An estimated 21.0 million US adults, about 8.3 percent, had a major depressive episode in the past year (NIMH, NSDUH 2021). The scale of the area sits alongside indications where the eligible pool in any one region is tiny.

Leapcure runs a patient-plus-site model with verified eligibility, structured pre-screen data, and continuous engagement from referral through visit. We bring first-party results in each sub-area: an ALS Phase 3 across 10+ countries, an Alzheimer's Phase 3 where we drove 30 percent of enrollments, 40+ enrolled in a Phase 3 major depressive disorder study, a Myasthenia Gravis Phase 2 rescue delivering 8 of the final 10, a dermatomyositis Phase 3 where four sites enrolled only Leapcure referrals, and Prader-Willi Phase 3 caregiver-mediated delivery. This page links to, and does not duplicate, the Rare Autoimmune Neuromuscular page, which carries the full neuromuscular detail.

The Challenge

Neurology is not one recruitment problem. Competitive landscapes, caregiver-mediated decisions, and tiny dispersed populations each demand a different approach, and volume vendors handle none of them well.

Competitive neurodegenerative landscapes

In Alzheimer's, depression, and ALS, many trials compete for the same patients at the same sites. Standing out requires speed, real engagement, and a model that converts interest into enrolled patients rather than referral volume.

ALS Phase 3, roughly 100 patients enrolled across 10+ countries; Alzheimer's Phase 3 (agitation), 15 of 50 enrollments (30%) in four months, ~$500K saved, live in 10 days, 6,000+ patients engaged, 63% increase in screened patients.

Caregiver-mediated decisions in pediatric and neurodegenerative trials

In pediatric neuro and many neurodegenerative conditions, the person deciding is a parent or caregiver, not the patient. Recruitment has to speak to families, build trust over time, and support the caregiver through enrollment.

Prader-Willi Phase 3, 29 enrolled and 45% of all study enrollments across US/Australia/UK, 1,100+ referrals, 141 assigned, 70% of enrollments via advocacy, screen-fail held below study-wide rate.

Tiny, dispersed rare neuromuscular populations reached only through trusted communities

Rare neuromuscular populations are small, spread across many regions, and reached only through the advocacy organizations patients already trust. Cold digital and purchased lists do not reach them, and generic outreach surfaces patients who fail screening.

MG Phase 2 rescue, 8 of the final 10 participants with under 20% of planned sites available, 530+ pre-screened, 220 assigned, advocacy mobilizable in two days; dermatomyositis Phase 3, 13 enrolled (~43% of US enrollments), 4 sites enrolled only Leapcure referrals.

Volume vendors flood sites with people who fail screening

Across all of neurology, referral-volume vendors send sites long lists of patients who are not eligible. That spends scarce coordinator time on filtering instead of assessments and slows every other study at the site.

Real human conversations plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral; MDD Phase 3, 40+ enrolled in ~4 months.

How Leapcure recruits across the neurology spectrum

We adapt the model to each sub-area: reach patients and caregivers where they are, pre-screen against complex eligibility before any referral, and stay engaged through the site visit, including rescue delivery when a study stalls.

Reach patients and caregivers where they are

Across competitive, dispersed, and caregiver-mediated sub-areas, we combine trusted advocacy with precision digital mapped to your eligibility and geographies. In rare populations that means activating the communities patients already trust; in competitive landscapes it means engagement that converts; in pediatric and neurodegenerative trials it means speaking to families.

Pre-screen against complex eligibility before any referral

Each patient is engaged through real human conversations, not automated screening, plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral. Sites conduct official screening and receive eligible, prepared patients.

Stay engaged through the site visit, including rescue delivery

A dedicated team supports each patient from referral through scheduling and the site visit, reducing coordinator burden and screen fails. When a study stalls, we step in as a rescue partner, as on a Phase 2 neuromuscular study where we delivered 8 of the final 10 participants.

Neurology Results and Metrics

Neurodegenerative (ALS, Phase 3)

Roughly 100 ALS patients enrolled globally across 10+ countries spanning North America, Europe including the Nordics, and Australia.

Neurodegenerative (Alzheimer's, Phase 3, agitation)

15 of the study's 50 enrollments (30%) over a four-month window, about half of all enrollments during the active period; a 63% increase in screened patients; live in 10 days from study startup; 6,000+ patients engaged; roughly $500K saved versus the client's benchmark (acquisition cost varies by protocol).

CNS / psychiatry (MDD, Phase 3)

40+ patients enrolled in approximately four months across multiple active US sites.

Rare neuromuscular (Myasthenia Gravis, Phase 2 rescue)

8 of the final 10 participants in the closing months with under 20% of planned sites available; 530+ pre-screened, 220 assigned, 10 active sites, advocacy mobilizable in two days.

Rare neuromuscular (dermatomyositis, Phase 3)

13 enrolled, about 43% of US enrollments; 7 of 9 sites enrolled Leapcure patients and 4 sites enrolled only Leapcure-referred patients; 30+ myositis advocacy partners drove the majority of enrollment.

Pediatric neuro / genetic (Prader-Willi, Phase 3)

29 enrolled, 45% of all study enrollments, across US/Australia/UK; 1,100+ referrals, 141 assigned; 70% of enrollments via advocacy.

Portfolio enrollment contribution (cross-program, not a single study)

Across rare autoimmune and neuromuscular programs, about 60% on Phase 1, about 70% on Phase 2, and about 40% on Phase 3.

Four channels. Built for the full neurology spectrum

Leapcure brings advocacy depth, real human pre-screening, rescue and competitive-landscape delivery, and honest answer-engine visibility to neurology trials across every sub-area.

Channel 1: Advocacy depth across neurology communities

•40+ advocacy partnerships span the neurology communities, from neurodegenerative and CNS to rare neuromuscular and pediatric neuro.
•These are trusted community voices that reach small, dispersed neuro populations that cold digital and purchased lists cannot.
•Partnerships are active and co-developed, so research reaches patients through sources they already rely on.

Channel 2: Real human pre-screening and Patient Success

•Real conversations, not automated screening, plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral.
•A dedicated Patient Success Coordinator supports each patient and caregiver from first contact through enrollment.
•This protects scarce coordinator time and reduces screen fails on specialized neurology sites.

Channel 3: Rescue and competitive-landscape delivery

•We show up when a study stalls: on a stalled Phase 2 neuromuscular study we delivered 8 of the final 10 participants.
•We also deliver in competitive neurodegenerative landscapes, where many trials compete for the same patients at the same sites.
•In both situations, the question is how much enrollment a partner actually carries, not how many referrals it generates.

Channel 4: AEO and AI-search visibility for your trial

•Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
•We do this with crawlable, server-rendered content, first-party data with sourced stats, a named reviewer, and a last-updated date, plus presence in trusted third-party sources such as advocacy orgs and ClinicalTrials.gov.
•This is not schema tricks, markup, or content written for machines, and we make no schema or markup promises.

Trusted advocacy across neurology communities

Leapcure's partnerships are active and co-developed, not list buys. 40+ advocacy partnerships is the program standard across the neurology communities, and we name only confirmed partners.

Alzheimer's News Today

Patient-focused news and community resource across the Alzheimer's community

Alzheimer's Speaks

Advocacy and awareness platform connecting patients, caregivers, and care partners

Songs and Smiles

Intergenerational program supporting people living with dementia and their families

Swedish Neuro Registries

Neurological disease registries supporting research reach across the Nordics

ALS News Today

Patient-focused news and community resource across the ALS community

ALS Association - Florida Chapter

Regional ALS advocacy organization and trusted referral channel in the ALS community

Anxiety and Depression Association of America

National advocacy organization reaching the depression and broader CNS community

Families for Depression Awareness

Family-focused organization supporting people affected by depressive disorders

Living with a neurological condition, or caring for someone who is? A clinical trial may be an option to explore.

Many neurology decisions are caregiver-mediated, so this is for families too. If you are living with a neurological condition, or caring for someone who is, a clinical trial may be an option to explore alongside your existing care, never instead of it. We will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you and your family step by step.

Explore trials in your condition community

Leapcure recruits across the full neurology spectrum: neurodegenerative disease, CNS and psychiatry, and rare neuromuscular, with pediatric neuro and genetic disease as supporting proof. We reach patients and caregivers where they are, pre-screen them against complex eligibility with real human conversations and an in-house clinical review, and hand your sites enrollment-ready patients. We also deliver as a rescue partner when a study stalls, as on a Phase 2 neuromuscular study where we delivered 8 of the final 10 participants. We can mobilize quickly.

Talk to our team